Ozempic & GLP-1 Weight Loss Drugs: Benefits, Risks, and What to Know

What GLP-1 Drugs Actually Are

GLP-1 receptor agonists (semaglutide — Ozempic/Wegovy, and tirzepatide — Mounjaro/Zepbound) are FDA-approved medications that mimic a natural gut hormone regulating appetite and blood sugar. They slow stomach emptying and act on appetite centers in the brain, which is why they produce such significant, consistent reductions in food intake and body weight.

Unlike SARMs, peptides, or steroids, these are legitimately approved drugs, backed by large clinical trials — the concern here isn't legitimacy, it's the real side effects and the way they're increasingly used outside proper medical supervision.

What They Actually Do Well

Produce substantial, clinically significant weight loss — considerably more than most prior weight-loss medications
Improve blood sugar control in type 2 diabetes, their original approved use
Show cardiovascular benefits in people with existing heart disease and obesity, based on large outcome trials
Reduce food-related cravings and "food noise" that many people describe as constant before treatment

The Common Side Effects

These are common enough that most users experience at least one, especially during dose increases:

Nausea, vomiting, and diarrhea, particularly when starting or increasing dose
Constipation, sometimes significant
Fatigue, and reduced appetite well beyond just food volume
Gallstones, with increased incidence during rapid weight loss

The Risk That Gets the Least Attention: Muscle Loss

Rapid weight loss from GLP-1 drugs isn't purely fat loss — a meaningful percentage of the weight lost is lean muscle mass, sometimes 25-40% of total weight lost in studies where body composition was measured. This matters because muscle drives metabolism, strength, and long-term function, especially in older adults.

The single most effective countermeasure is straightforward: adequate protein intake and continued resistance training throughout treatment, which meaningfully preserves lean mass compared to weight loss without those habits.

Serious but Less Common Risks

Pancreatitis: rare but serious inflammation of the pancreas has been reported
Thyroid tumors: a boxed warning exists based on animal studies showing thyroid C-cell tumors; the human risk is still being studied, and the drugs are not recommended for people with a personal or family history of certain thyroid cancers
Gallbladder disease: increased risk of gallstones requiring treatment
Severe gastrointestinal effects: in rare cases, significantly delayed stomach emptying causing complications, particularly relevant for anesthesia and surgery

The Compounded Pharmacy Problem

Due to shortages, a large market emerged for "compounded" semaglutide and tirzepatide from pharmacies not held to the same manufacturing standards as the FDA-approved product. Reports of dosing errors, contamination, and adverse events have followed, and regulators in several countries have issued specific warnings about compounded versions. This is a genuinely different risk category from the approved, pharmacy-dispensed brand-name product.

Who Should Be Cautious

Anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome
Anyone with a history of pancreatitis
Anyone sourcing the medication outside a licensed pharmacy with proper prescribing and monitoring
Anyone using it without addressing protein intake and resistance training, given the muscle loss risk

The Bottom Line

GLP-1 medications are a genuine, evidence-backed medical advance for obesity and type 2 diabetes — not a scam or a fad in the way SARMs or peptides are. But they're still medications with real side effects, a meaningful muscle-loss risk that's rarely discussed on social media, and a growing compounded-pharmacy market with its own separate safety concerns. Used through a licensed provider, with adequate protein and resistance training alongside it, the risk-benefit picture looks very different than used through an unregulated online source.